TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer (original) (raw)

• Backhed F, Hornef M . (2003). Toll-like receptor 4-mediated signaling by epithelial surfaces: necessity or threat? Microbes Infect 5: 951–959.
  Article CAS PubMed Google Scholar
• Bayry J, Lacroix-Desmazes S, Donkova-Petrini V, Carbonneil C, Misra N, Lepelletier Y et al. (2004). Natural antibodies sustain differentiation and maturation of human dendritic cells. Proc Natl Acad Sci USA 101: 14210–14215.
  Article CAS PubMed PubMed Central Google Scholar
• Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie KG et al. (1987). Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 47: 414–418.
  CAS PubMed Google Scholar
• Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA et al. (1999). Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 10 (Suppl 1): 87–92.
  Article PubMed Google Scholar
• Blagosklonny MV, Fojo T . (1999). Molecular effects of paclitaxel: myths and reality (a critical review). Int J Cancer 83: 151–156.
  Article CAS PubMed Google Scholar
• Brewer MA, Johnson K, Follen M, Gershenson D, Bast Jr R . (2003). Prevention of ovarian cancer: intraepithelial neoplasia. Clin Cancer Res 9: 20–30.
  CAS PubMed Google Scholar
• Byrd-Leifer CA, Block EF, Takeda K, Akira S, Ding A . (2001). The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol. Eur J Immunol 31: 2448–2457.
  Article CAS PubMed Google Scholar
• Chuang T, Ulevitch RJ . (2001). Identification of hTLR10: a novel human Toll-like receptor preferentially expressed in immune cells. Biochim Biophys Acta 1518: 157–161.
  Article CAS PubMed Google Scholar
• Cimoli G, Malacarne D, Ponassi R, Valenti M, Alberti S, Parodi S . (2004). Meta-analysis of the role of p53 status in isogenic systems tested for sensitivity to cytotoxic antineoplastic drugs. Biochim Biophys Acta 1705: 103–120.
  CAS PubMed Google Scholar
• Cuello M, Ettenberg SA, Nau MM, Lipkowitz S . (2001). Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Gynecol Oncol 81: 380–390.
  Article CAS PubMed Google Scholar
• Duan Z, Duan Y, Lamendola DE, Yusuf RZ, Naeem R, Penson RT et al. (2003). Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin Cancer Res 9: 2778–2785.
  CAS PubMed Google Scholar
• Duan Z, Feller AJ, Toh HC, Makastorsis T, Seiden MV . (1999). TRAG-3, a novel gene, isolated from a taxol-resistant ovarian carcinoma cell line. Gene 229: 75–81.
  Article CAS PubMed Google Scholar
• Eskan MA, Rose BG, Benakanakere MR, Lee MJ, Kinane DF . (2008). Sphingosine 1-phosphate 1 and TLR4 mediate IFN-beta expression in human gingival epithelial cells. J Immunol 180: 1818–1825.
  Article CAS PubMed Google Scholar
• Fitzpatrick FA, Wheeler R . (2003). The immunopharmacology of paclitaxel (Taxol), docetaxel (Taxotere), and related agents. Int Immunopharmacol 3: 1699–1714.
  Article CAS PubMed Google Scholar
• Fukata M, Abreu MT . (2008). Role of Toll-like receptors in gastrointestinal malignancies. Oncogene 27: 234–243.
  Article CAS PubMed PubMed Central Google Scholar
• Gallardo D, Drazan KE, McBride WH . (1996). Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity. Cancer Res 56: 4891–4893.
  CAS PubMed Google Scholar
• Girling JE, Hedger MP . (2007). Toll-like receptors in the gonads and reproductive tract: emerging roles in reproductive physiology and pathology. Immunol Cell Biol 85: 481–489.
  Article CAS PubMed Google Scholar
• He W, Liu Q, Wang L, Chen W, Li N, Cao X . (2007). TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol 44: 2850–2859.
  Article CAS PubMed Google Scholar
• Hefler LA, Grimm C, Ackermann S, Malur S, Radjabi-Rahat AR, Leodolter S et al. (2003). An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. Cancer Res 63: 3066–3068.
  CAS PubMed Google Scholar
• Hollstein M, Soussi T, Thomas G, von Brevern MC, Bartsch H . (1997). P53 gene alterations in human tumors: perspectives for cancer control. Recent Results Cancer Res 143: 369–389.
  Article CAS PubMed Google Scholar
• Huang X, Barrett RP, McClellan SA, Hazlett LD . (2005). Silencing Toll-like receptor-9 in Pseudomonas aeruginosa keratitis. Invest Ophthalmol Vis Sci 46: 4209–4216.
  Article PubMed Google Scholar
• Jordan MA, Wilson L . (2004). Microtubules as a target for anticancer drugs. Nat Rev Cancer 4: 253–265.
  Article CAS PubMed Google Scholar
• Kassim SK, El-Salahy EM, Fayed ST, Helal SA, Helal T, Azzam Eel D et al. (2004). Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem 37: 363–369.
  Article CAS PubMed Google Scholar
• Kawasaki K, Akashi S, Shimazu R, Yoshida T, Miyake K, Nishijima M . (2001). Involvement of TLR4/MD-2 complex in species-specific lipopolysaccharide-mimetic signal transduction by Taxol. J Endotoxin Res 7: 232–236.
  Article CAS PubMed Google Scholar
• Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S et al. (2006). TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 66: 3859–3868.
  Article CAS PubMed Google Scholar
• Kreuz S, Siegmund D, Rumpf JJ, Samel D, Leverkus M, Janssen O et al. (2004). NFkappaB activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by FLIP. J Cell Biol 166: 369–380.
  Article CAS PubMed PubMed Central Google Scholar
• Landen Jr CN, Birrer MJ, Sood AK . (2008). Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 26: 995–1005.
  Article PubMed Google Scholar
• Lauzon NM, Mian F, MacKenzie R, Ashkar AA . (2006). The direct effects of Toll-like receptor ligands on human NK cell cytokine production and cytotoxicity. Cell Immunol 241: 102–112.
  Article CAS PubMed Google Scholar
• Lokshin AE, Winans M, Landsittel D, Marrangoni AM, Velikokhatnaya L, Modugno F et al. (2006). Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecol Oncol 102: 244–251.
  Article CAS PubMed Google Scholar
• MacRedmond R, Greene C, Taggart CC, McElvaney N, O'Neill S . (2005). Respiratory epithelial cells require Toll-like receptor 4 for induction of human beta-defensin 2 by lipopolysaccharide. Respir Res 6: 116.
  Article PubMed PubMed Central Google Scholar
• Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC, LaFace DM et al. (1995). Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med 182: 1545–1556.
  Article CAS PubMed Google Scholar
• Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM, Brem H . (2007). Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf 6: 609–621.
  Article CAS PubMed Google Scholar
• McClure N, Healy DL, Rogers PA, Sullivan J, Beaton L, Haning Jr RV et al. (1994). Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 344: 235–236.
  Article CAS PubMed Google Scholar
• Molteni M, Marabella D, Orlandi C, Rossetti C . (2006). Melanoma cell lines are responsive in vitro to lipopolysaccharide and express TLR-4. Cancer Lett 235: 75–83.
  Article CAS PubMed Google Scholar
• Penson RT, Kronish K, Duan Z, Feller AJ, Stark P, Cook SE et al. (2000). Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer 10: 33–41.
  Article PubMed Google Scholar
• Petty R, Evans A, Duncan I, Kurbacher C, Cree I . (1998). Drug resistance in ovarian cancer—the role of p53. Pathol Oncol Res 4: 97–102.
  Article CAS PubMed Google Scholar
• Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF . (1983). Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983–985.
  Article CAS PubMed Google Scholar
• Siervo-Sassi RR, Marrangoni AM, Feng X, Naoumova N, Winans M, Edwards RP et al. (2003). Physiological and molecular effects of Apo2L/TRAIL and cisplatin in ovarian carcinoma cell lines. Cancer Lett 190: 61–72.
  Article CAS PubMed Google Scholar
• Strauss L, Whiteside TL, Knights A, Bergmann C, Knuth A, Zippelius A . (2007). Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol 178: 320–329.
  Article CAS PubMed Google Scholar
• Szczepanski M, Stelmachowska M, Stryczynski L, Golusinski W, Samara H, Mozer-Lisewska I et al. (2007). Assessment of expression of toll-like receptors 2, 3 and 4 in laryngeal carcinoma. Eur Arch Otorhinolaryngol 264: 525–530.
  Article PubMed Google Scholar
• Szczepanski MJ, Czystowska M, Szajnik M, Harasymczuk M, Boyiadzis M, Kruk-Zagajewska A et al. (2009). Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res 69: 3105–3113.
  Article CAS PubMed PubMed Central Google Scholar
• Takeda K, Akira S . (2007). TLR signaling. Sem Immunol 19: 24–32.
  Article Google Scholar
• Takeda K, Kaisho T, Akira S . (2003). Toll-like receptors. Annu Rev Immunol 21: 335–376.
  Article CAS PubMed Google Scholar
• Takeuchi O, Kawai T, Sanjo H, Copeland NG, Gilbert DJ, Jenkins NA et al. (1999). TLR6: a novel member of an expanding toll-like receptor family. Gene 231: 59–65.
  Article CAS PubMed Google Scholar
• Tanimura N, Saitoh S, Matsumoto F, Akashi-Takamura S, Miyake K . (2008). Roles for LPS-dependent interaction and relocation of TLR4 and TRAM in TRIF-signaling. Biochem Biophys Res Commun 368: 94–99.
  Article CAS PubMed Google Scholar
• Taxman DJ, MacKeigan JP, Clements C, Bergstralh DT, Ting JP . (2003). Transcriptional profiling of targets for combination therapy of lung carcinoma with paclitaxel and mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor. Cancer Res 63: 5095–5104.
  CAS PubMed Google Scholar
• Wang TH, Chan YH, Chen CW, Kung WH, Lee YS, Wang ST et al. (2006). Paclitaxel (Taxol) upregulates expression of functional interleukin-6 in human ovarian cancer cells through multiple signaling pathways. Oncogene 25: 4857–4866.
  Article CAS PubMed Google Scholar
• Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV . (2003). Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 3: 1–19.
  Article CAS PubMed Google Scholar
• Zhang D, Zhang G, Hayden MS, Greenblatt MB, Bussey C, Flavell RA et al. (2004). A toll-like receptor that prevents infection by uropathogenic bacteria. Science 303: 1522–1526.
  Article CAS PubMed Google Scholar